Study of Prognostic Factors Associated With Overall Survival in Patients Initially Treated for Advanced Ovarian and/or Peritoneum and/or Fallopian Tubes Carcinoma: Analysis Using a Prospective Clinico-Biological Database

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Cancer of the ovary and/or peritoneum and/or fallopian tube have a very poor prognosis, and require the implementation of collaborative research tools and new innovative therapies. The main objective of this study is to implement prognostic model of overall survival on patients included prospectively as part of the initial treatment of advanced ovarian and/or peritoneum, and/or fallopian tubes carcinoma (this cohort corresponds to the Turquoise care pathway of the Oscar Lambret Center) regardless of the treatment carried out,, integrating both patient's and tumor's characteristics. A clinical and biological database is implemented for this purpose. 371 patients will be recruited over a 5-year period at the Oscar Lambret Center. The active participation of each patient will be 2 years (from the date of inclusion until the end of study participation, defined by the date of the last intervention specific to the research), then the data from standard care and survival data will be collected until the last follow-up of the last patient, 2 years after the last inclusion.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:

• Patient aged 18 or over

• Informed consent warranted

• Patient affiliated to a social security regimen

• Suspected or confirmed diagnosis of advanced and invasive ovarian cancer and/or primary peritoneal cancer and/or fallopian tube cancer (IIB to IV FIGO stages)

• Inclusion during standard care at the Oscar Lambret Centre, from diagnosis to the day of surgery

Locations
Other Locations
France
Centre Oscar Lambret
RECRUITING
Lille
Contact Information
Primary
Alicia Probst, PhD
promotion@o-lambret.fr
33320295918
Backup
Lucie BRESSON, MD, PhD
33320295918
Time Frame
Start Date: 2025-06-27
Estimated Completion Date: 2032-06-27
Participants
Target number of participants: 371
Treatments
Experimental: Clinical and Biological Collection
Related Therapeutic Areas
Sponsors
Leads: Centre Oscar Lambret

This content was sourced from clinicaltrials.gov

Similar Clinical Trials